These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34507114)

  • 21. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
    Lynch DR; Perlman SL; Meier T
    Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antioxidants and other pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Pandolfo M
    Cochrane Database Syst Rev; 2012 Apr; (4):CD007791. PubMed ID: 22513953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic evaluation of idebenone.
    Becker C; Bray-French K; Drewe J
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1437-44. PubMed ID: 20955109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idebenone: an emerging therapy for Friedreich ataxia.
    Meier T; Buyse G
    J Neurol; 2009 Mar; 256 Suppl 1():25-30. PubMed ID: 19283347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.
    Drinkard BE; Keyser RE; Paul SM; Arena R; Plehn JF; Yanovski JA; Di Prospero NA
    Arch Phys Med Rehabil; 2010 Jul; 91(7):1044-50. PubMed ID: 20599042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients.
    Artuch R; Aracil A; Mas A; Monrós E; Vilaseca MA; Pineda M
    Neuropediatrics; 2004 Apr; 35(2):95-8. PubMed ID: 15127307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
    Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A
    Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with high-dose idebenone in Friedreich ataxia.
    Schulz JB; Di Prospero NA; Fischbeck K
    J Neurol; 2009 Mar; 256 Suppl 1(0 1):42-5. PubMed ID: 19283350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antioxidants and other pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Pandolfo M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007791. PubMed ID: 19821439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
    Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).
    Lagedrost SJ; Sutton MS; Cohen MS; Satou GM; Kaufman BD; Perlman SL; Rummey C; Meier T; Lynch DR
    Am Heart J; 2011 Mar; 161(3):639-645.e1. PubMed ID: 21392622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy.
    Cooper JM; Korlipara LV; Hart PE; Bradley JL; Schapira AH
    Eur J Neurol; 2008 Dec; 15(12):1371-9. PubMed ID: 19049556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of idebenone in plasma by HPLC with post-column fluorescence derivatization using 2-cyanoacetamide.
    Nohara Y; Suzuki J; Yamazaki Y; Kubo H
    Chem Pharm Bull (Tokyo); 2012; 60(5):598-602. PubMed ID: 22689397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction. Idebenone in the treatment of Friedreich ataxia.
    Pandolfo M
    J Neurol; 2009 Mar; 256 Suppl 1():1-2. PubMed ID: 19283343
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of antioxidants in Friedreich's ataxia treatment.
    Rustin P
    Expert Opin Investig Drugs; 2003 Apr; 12(4):569-75. PubMed ID: 12665413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring.
    Buyse G; Mertens L; Di Salvo G; Matthijs I; Weidemann F; Eyskens B; Goossens W; Goemans N; Sutherland GR; Van Hove JL
    Neurology; 2003 May; 60(10):1679-81. PubMed ID: 12771265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idebenone in Friedreich ataxia and Leber's hereditary optic neuropathy: close mechanisms, similar therapy?
    Schiff M; Rustin P
    Brain; 2016 Jul; 139(Pt 7):e39. PubMed ID: 27095078
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.
    Elincx-Benizri S; Glik A; Merkel D; Arad M; Freimark D; Kozlova E; Cabantchik I; Hassin-Baer S
    J Child Neurol; 2016 Jul; 31(8):1036-40. PubMed ID: 27029487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
    Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
    Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
    Zesiewicz T; Salemi JL; Perlman S; Sullivan KL; Shaw JD; Huang Y; Isaacs C; Gooch C; Lynch DR; Klein MB
    Neurodegener Dis Manag; 2018 Aug; 8(4):233-242. PubMed ID: 30051753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.